• Dr. Sohail Ahmed has a long and successful track record in clinical management at large Pharma and biotech companies, including Novartis Pharma, Novartis Vaccines, GSK Vaccines, Roche Pharma, and Galapagos

KELI Therapeutics appoints Dr. Sohail Ahmed as Director on the Board

4th September 2024, Kaunas, Lithuania

KELI Therapeutics is researching and delivering innovative treatments for unmet medical needs. We develop and manufacture cellular therapies and have extracellular vesicle (EV) therapeutic production in our own Good Manufacturing Practice (GMP) facility targeting immunology and inflammatory conditions.

Dr. Justinas Maciulaitis, CEO and Founder of KELI Therapeutics, said, “We are on an ambitious plan to start our clinical trial for Acute Kidney Injury (AKI) and to identify the best possible future indications. On this background, we wanted to strengthen our Board with a person who has experience in these activities. With Sohail’s extensive Pharma background and experience in small biotech start-ups, we are now better equipped to engage in clinical collaborations.”

Dr. Sohail Ahmed said, “I am pleased to join KELI at this junction as there are so many interesting opportunities for a stem cell company. We see how cellular therapy is gaining sales and expanding its indications, and on top of this, we have unexploited opportunities with exosomes and EVs.”

About KELI Therapeutics

Funded in 2019, KELI Therapeutics already has many publications (please review here) covering cartilage regeneration and mesenchymal stromal cell research. In 2025, this will result in KELI Therapeutics providing clinical services out of Lithuania and initiating clinical trial activities for a highly unmet medical need - acute Kidney Injury - and a pipeline of inflammatory disorders.

Utilizing stromal stem cells from perinatal tissues and by taking advantage of KELI’s effective and proprietary manufacturing methods, high yields of relevant cells and EVs are consistently obtained. Further proprietary processing results in potent products for the benefit of patients worldwide. Strategically co-located with the largest Central European Health Sciences University and Hospital, KELI Therapeutics thrives in a dynamic ecosystem of research, development, and commercialization. This prime location fosters diverse collaborations and accelerates our mission to bring cutting-edge treatments to market.

For further information, please contact Dr. Justinas Maciulaitis at +370 690 22777 or Info@keli.eu. You may also visit our website – www.keli.eu

• With a focus on autoimmunity, immunology, and inflammation, Sohail will be well-placed to help and assist KELI in its clinical activities

• Sohail appointment to the Board will ensure that KELI makes the right decisions on the clinical strategy and product pipeline